Myriad Genetics Stock Price, News & Analysis

Myriad Genetics (NASDAQ: MYGN) announced it will present 8 abstracts at the 2025 San Antonio Breast Cancer Symposium (SABCS) on Dec. 10–11, 2025, covering MRD, germline testing, somatic profiling, and polygenic risk.

Key highlights include new data on the Precise Molecular Residual Disease (MRD) Test—a tumor-informed, WGS-based assay with custom selection of up to 1,000 variants and reported ultra-sensitivity at low tumor fractions (RUO)—and updates to the MyRisk Hereditary Cancer Test expanded to 63 genes. Myriad will sponsor a Product Theater session on Dec. 10 (2:30–3:30 p.m. CST) and host a booth (#1414) during exhibition hours.

Myriad Genetics (NASDAQ: MYGN), Clairity, and MagView announced a collaboration on Nov 25, 2025 to deliver the first integrated platform combining genotype and AI-derived phenotype for breast cancer risk assessment.

The integration links Myriad’s MyRisk with RiskScore hereditary cancer test, Clairity Breast (the FDA-authorized AI mammogram risk estimator), and MagView’s Luminary Risk workflow to provide clinicians a unified, actionable view of five-year breast cancer risk from routine mammograms and genetics.

The partners say the platform aims to identify more women at elevated risk and support earlier, personalized interventions while preserving clinical workflow efficiency.

Myriad Genetics (NASDAQ: MYGN) said its management will participate in two investor healthcare conferences in late 2025. Wolfe Research Healthcare Conference — fireside chat on Nov. 18, 2025 at 1:20 pm ET. Piper Sandler Healthcare Conference — fireside chat on Dec. 2, 2025 at 12:00 pm ET. Both presentations will be available via live audio webcasts in the investor information section at investor.myriad.com.

Myriad Genetics (NASDAQ: MYGN) expanded its MyRisk® Hereditary Cancer Test on Nov 10, 2025 to include genes referenced in NCCN and ASCO guidelines.

The updated MyRisk panel now includes 63 genes covering more than 11 cancer types, and the company says it includes 100% of genes strongly recommended by national oncology guidelines to support treatment decisions, surveillance planning, and family risk assessment.

Results are available via paper requisition, the Myriad patient portal and multiple EMR platforms including EPIC.

Myriad Genetics (NASDAQ: MYGN) will present 11 new research studies at the National Society of Genetic Counselors 44th Annual Conference on Nov. 7–8, 2025, highlighting oncology and reproductive genetic testing advances.

Featured products include MyRisk Hereditary Cancer Test, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen, and Foresight Carrier Screen. Myriad will exhibit at booth #317 and share poster presentations on topics such as RNA analysis for VUS interpretation, fetal fraction amplification for early cfDNA screening, prenatal cfDNA detecting maternal colorectal cancer, automated FXN repeat detection, and genetics education and recontact workflows.

Myriad Genetics (NASDAQ: MYGN) reported third quarter 2025 results: revenue $205.7M (down 4% YoY, flat ex‑$8.1M headwinds), gross margin 69.9%, GAAP net loss $27.4M (loss per share $0.29) and adjusted EPS $0.00. Third quarter adjusted EBITDA was $10.3M and test volumes rose to 386,000 (+3% YoY), led by hereditary cancer volume +11%.

The company entered a strategic collaboration with SOPHiA GENETICS for liquid biopsy CDx development, closed a $200M term loan in July, and ended the quarter with $145.4M cash. Myriad reiterated full‑year 2025 guidance: Revenue $818–$828M, gross margin 69.5%–70.0%, adjusted EBITDA $27–$33M, adjusted EPS $(0.02)–$0.02.

Myriad Genetics (NASDAQ: MYGN) reported a post-hoc analysis of the PRIME study showing GeneSight-informed treatment produced faster remission and response in major depressive disorder.

The PRIME trial enrolled 1,944 U.S. Veterans. The analysis, published Oct 30, 2025 in Frontiers in Pharmacology, found GeneSight patients were 27% more likely to achieve remission and 21% more likely to experience response at any time during the 24-week study, with benefits persisting through six months. Myriad plans to submit these data to payers to support access to GeneSight.

Myriad Genetics (NASDAQ: MYGN) will release its third quarter 2025 financial results on November 3, 2025 after market close and will host an earnings conference call the same day at 4:30 PM ET. Management will provide a financial overview and business update for Q3 2025.

A live webcast will be available on Myriad’s Investor Relations website at investor.myriad.com. Telephone participants must register to receive a dial-in number and unique PIN. An archived webcast will be posted at investor.myriad.com following the call.

Myriad Genetics (NASDAQ: MYGN) announced on October 14, 2025 that it added the F8 and FXN genes to the Foresight® Carrier Screen Universal Plus Panel. The company said the additions meet its clinical-selection criteria and that testing is processed in its state-of-the-art facility.

The update makes the Foresight Carrier Screen fully compliant with ACMG recommendations. The release notes F8's link to hemophilia A and FXN's link to Friedreich's ataxia and references the FDA's 2023 approval of omaveloxolone for FA in patients aged 16+.